Maximilien holds a Master in Biology, a PhD from the Swiss Institute of Experimental Cancer Research, and an executive MBA from the Faculty of Business and Economics, HEC Lausanne.
He joined Cellestia as the Chief Operating Officer in 2017 with more than 20 years of experience in operations, business development and project management in several life science companies. Before joining Cellestia, Maximilien served as the Managing Director for AdipoGen Life Sciences where he led the operations of the R&D and production site in Switzerland.
“I am looking for our drugs to show such a level of clinical efficacy in treating NOTCH-driven cancers, that doors are opened to possibilities beyond our imaginations.”
In addition, Maximilien served as an Associate Director at Debiopharm International SA, where he was responsible for managing the pre-clinical portfolio, in-licensing new oncology programs, and leading the Early Projects team.